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Only a small fraction of the peptides generated inside the cell end up being presented by HLA-I on
the cell surface. High stability of peptide–HLA-I complexes and a low HLA-I tapasin-facilitation have
been proposed to predict immunogenicity. We here set out to investigate if these parameters corre-
lated and deﬁned immunogenic peptides. Both peptide–HLA–B⁄08:01 and peptide–HLA–A⁄02:01
complexes showed small differences in tapasin-facilitation and larger differences in stability. This
suggests that the stability of immunogenic peptide–HLA-I complexes vary above an HLA-I allomorph
dependent lower limit (e.g. >2 h for HLA–A⁄02:01), immunogenicity predicted by tapasin-facilitation
may be deﬁned by an equally allomorph unique upper value (e.g. tapasin-facilitation <1.5 for HLA–
A⁄02:01), and variation above the stability-threshold does not directly reﬂect a variation in tapasin-
facilitation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human leukocyte antigen class I (HLA-I) molecules present pep-
tides to CD8+ T-cells, and are crucial in the clearance of viral patho-
gens and of cells in the process of malignant transformation. The
peptide–HLA-I (pHLA-I) complex is formed in a highly regulated
process, in which several different ER proteins work together to as-
sure the formation of stable pHLA-I complexes. Once the HLA-I
heavy chain (HC) has associated with b2-microglobulin (b2m), the
HLA-I molecule is bridged by tapasin to the transporter associated
with antigen processing (TAP), thereby forming the peptide-load-
ing complex (PLC), which also consist of calreticulin (Crt) and
ERp57 [1]. Inside the PLC, HLA-I is kept in a peptide-receptive state
until an optimal peptide is bound. Peptide-receptive and subopti-
mally peptide-loaded HLA-I molecules are suggested to be both
chaperoned and retained in the ER by tapasin until a peptide
inducing a stable pHLA-I complex have bound. Binding of optimal
peptides induces release of pHLA-I from tapasin and egress to the
cell surface.
In the PLC, tapasin is believed to play a key role in the late stage
maturation of HLA-I molecules, allowing cell surface expression ofchemical Societies. Published by E
BMC-D14, Lund University,
den.
aulsson).stable pHLA-I complexes. Since its discovery, tapasin has been
attributed several functions – to increase the available local pep-
tide concentration by bridging HLA-I molecules to TAP [2–4], to
stabilize TAP expression and improve its capacity to bind peptide
prior to the translocation step [5–8], to keep HLA-I molecules pep-
tide-receptive in the PLC [9–11], to recycle empty or suboptimally
loaded HLA-I molecules back to the ER [4,12–14], and, to act as a
peptide-editor, allowing exchange of suboptimal peptides for opti-
mal peptides [1,15,16]. However, the exact molecular mechanisms
of the tapasin-mediated HLA-I quality control remain unknown.
The optimization process is suggested to work towards pHLA-I
molecules of higher stability but the boundaries in half-lives deﬁn-
ing immunogenic pHLA-I complexes are poorly deﬁned.
From the law of mass action, the equilibrium dissociation con-
stant (KD, a measure of afﬁnity) of a bimolecular receptor–ligand
interaction is equal to the ratio of the rate of dissociation (kd, the
dissociation rate coefﬁcient) to the rate of association (ka, the asso-
ciation rate coefﬁcient):
KD ¼ kd=ka ð1Þ
Under conditions of limited HLA-I (receptor) concentration and
high peptide (ligand) concentration EC50 is a reasonable approxi-
mation of KD (i.e. afﬁnity). The off-rate/dissociation-rate coefﬁ-
cient is here a measure of stability. Since the HLA-I HC – b2m
dimer is highly unstable in the absence of peptide and it has been
demonstrated that dissociation of 125I-labeled b2m preciselylsevier B.V. All rights reserved.
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of b2m as a measure of peptide dissociation [17]. Given the law of
mass action, afﬁnity and stability are related but do not always
follow each other, e.g. high afﬁnity does not always correspond
to high stability. Although a general perception of afﬁnity is a
good measurement of potential immunogenicity, different studies
have indeed suggested stability as a more reliable parameter
[18,19]. In this study we selected HLA–A⁄02:01 and HLA–
B⁄08:01 binding peptides from the SYFPEITHI database (i.e. natu-
ral ligands largely deﬁned as being immunogenic), determined
folding and stability of these pHLA-I complexes, and studied com-
plex formation and dissociation under the inﬂuence of Tpn1–87
(amino acids 1–87 of the mature tapasin protein [20]). Although
all peptides were of high afﬁnity the stability varied and also to
some extent the ratio of the increase in Bmax (Bmax = amount
pHLA-I complex formed) in presence and absence of Tpn1–87,
termed tapasin-facilitation. The hierarchy between pHLA-I com-
plexes based on changes in tapasin-facilitation did not correlate
with the, slightly larger, changes in stability. Moreover, the
effects of Tpn1–87 were more pronounced on HLA–B⁄08:01 than
HLA–A⁄02:01, and absent on the tapasin-independent allomorph
HLA-A⁄02:01-T134K, in line with the previously established hier-
archy of tapasin-dependency for these HLA-I molecules [21].
Although stability is a good tool to predict immunogenicity, a
change in stability not necessarily equals a change in immunoge-
nicity. Moreover, the lower limit of stabilities deﬁning immuno-
genic pHLA-I complexes differs for different HLA-I allomorphs
and makes predictions of immunogenicity more complicated.
Similarly, predictions based on a low-degree of tapasin-facilitation
should be done ﬁrst after determining the upper limit of tapasin-
facilitation for immunogenic peptides for the speciﬁc allomorphs
studied. Although a previous study of large sets of HLA–A⁄02:01
non-SYFPPEITHI and SYFPEITHI peptides indicated that the
tapasin-facilitation and the stability to a very high degree of
speciﬁcity discriminate SYFPEITHI peptides from non-SYFPEITHI
peptides [18], and although the peptides studied here for both
HLA–A⁄02:01 and HLA-B⁄08:01 are all deﬁned by both a reason-
able high stability (over 2 and 1.5 h half-life respectively) and a
low tapasin-facilitation (less than 1.5 and 1.8 respectively),
studies have shown that stability does not always correlate with
immunogenicity [22]. Hence, we propose that for best sensitivity,
and to a lesser extent speciﬁcity, both stability and tapasin-
facilitation thresholds should be determined and used as
complementary tools in the development of candidates for
peptide-based vaccines.
2. Materials and methods
2.1. Peptides
All peptides were purchased from Schafer-N (Denmark). Pep-
tides intended to be used in setups with 125I-labeling the sequence
of the original SYFPEITHI peptides were modiﬁed. Ataxin324–333
(QVFPGLLERV) was modiﬁed with substitutions of F to Y, and R
to K, resulting in the QVY peptide, QVYPGLLEKV. Ribosomal protein
L10a8–16 (TLYEAVREV) was modiﬁed with substitution of E to K,
resulting in the TLY peptide, TLYEAVRKV. Cadherin 17 precur-
sor2–10 (ILQAHLHSL) was modiﬁed with substitutions of Q to Y,
and of S to K, resulting in the ILY peptide, ILYAHLHKL. FLRGRAYGL
(EBV EBNA3A), QAKWRLQTL (EBV EBNA3) and ELRSRYWAI (Inﬂu-
enza A) were synthesized as original SYFPEITHI sequences. Brieﬂy,
all peptides were synthesized (Applied Biosystems, model 431A),
using conventional F-moc (N-(9-ﬂuorenyl) methoxycarbonyl)
chemistry. The peptides were subsequently puriﬁed by RP-HPLC
and dissolved in PBS.2.2. Peptide–HLA-I folding assay
Peptide–HLA-I (pHLA-I) folding was monitored in a lumines-
cence oxygen chanelling immuno (LOCI) assay (commercialized
as ampliﬁed luminescence proximity based homogenous assay
(AlphaScreen)) as previously described [20,23]. Brieﬂy, 2 nM bio-
tinylated recombinant HLA-I HCs were diluted in a buffer contain-
ing different concentrations of peptide, recombinant human 30 nM
b2m and presence or absence of 20 nM Tpn1–87. The reaction mix-
tures were incubated at 18 C for 48 h to allow pHLA-I complex for-
mation to reach steady-state. pHLA-I complexes were quantiﬁed in
a W6/32-based AlphaScreen assay, which recognizes folded pHLA-I
complexes. Detection of folded pHLA-I complexes was done by
adding 15 ll folding reaction to 15 ll PBS containing 10 lg/ml of
AlphaScreen Donor beads (PerkinElmer, 6760002; conjugated with
streptavidin) and Acceptor beads (PerkinElmer, 6762001; in-house
conjugated with the W6/32 antibody). The plates were incubated
at 18 C over-night, and then equilibrated to reader temperature
for 1 h, and subsequently read in a plate-reader (EnVision™, Perkin
Elmer). The conversion of AlphaScreen signal to concentrations of
folded pHLA-I complex was done using a pre-folded pHLA–
A⁄02:01 standard of known concentration.
2.3. Peptide–HLA-I stability assay
To measure stabilities of pHLA-I complexes a biochemical prox-
imity assay was used [24]. Brieﬂy, 50 nM biotinylated HLA-I HC,
125I-labeled b2m (ﬁnal speciﬁc activity of 125 cpm/ll), and 1 lM
of an appropriate strong binding peptide was incubated in the
presence or absence of 500 nM Tpn1–87. The reactions were incu-
bated in a streptavidin coated FlashPlate (PerkinElmer, SMP103)
at 18 C for 24 h. Dissociation of the pHLA-I complexes was initi-
ated by adding excess (1 lM) of unlabeled b2m followed by contin-
uous reading in a liquid scintillation counter (TopCount NXT,
Perkin Elmer) thermostated to 37 C. The half-lives were calculated
from the dissociation curves using Prism 5 (GraphPad). Non-linear
regression was made with least squares ﬁt. To compare models, an
extra sum of square F-test was done, and more complex curve ﬁt
model was selected when the null-hypothesis could be rejected
(i.e. P < 0.05). Dissociation data were in all cases ﬁt to biphasic
dissociation equations (P-value < 0.0001) with the plateau set to
zero.
3. Results
3.1. SYFPEITHI peptides of high afﬁnity bind to both HLA–A⁄02:01 and
HLA–B⁄08:01, but Tpn1–87 facilitates complex formation only with
HLA–B⁄08:01 to a signiﬁcant extent
To study the role of tapasin in HLA-I maturation we have previ-
ously produced a recombinant protein consisting of the ﬁrst 87
amino acids of tapasin, Tpn1–87 [20]. When Tpn1–87 was present
during de novo folding of recombinant HLA–A⁄02:01 we observed
that an increased amount of pHLA–A⁄02:01 complexes was gener-
ated. These observations, together with recent results for different
HLA-I molecules (i.e. HLA–B⁄44:02, HLA–B⁄08:01, HLA–A⁄02:01,
HLA–A⁄02:01(T134K), and HLA–B⁄27:05), suggest that Tpn1–87
facilitates folding of pHLA-I complexes to a degree depending on
both the peptide and HLA-I HC identity [18]. Importantly, Tpn1–87
was shown to discriminate HLA–A⁄02:01 immunogenic peptides
(i.e. peptides reported in the SYFPEITHI database as natural MHC-
I ligands) from non-immunogenic HLA–A⁄02:01 binding peptides
of equal afﬁnity. Moreover, stability analysis of pHLA–A⁄02:01
complexes suggested that also the stability of pHLA-I complexes
is a good parameter to identify immunogenic peptides among
Table 2
Afﬁnities determined from dose response curves of peptides binding to HLA–A⁄02:01
and HLA–B⁄08:01 as analyzed after folding with AlphaScreen assay.
Peptide EC50 (nM)
ILYAHLHKL <1
QVYPGLLEKV <1
TLYEAVRKV <1
FLRGRAYGL 16
QAKWRLQTL 69
ELRSRYWAI 12
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investigate the two parameters, that both can be used to deﬁne
immunogenic peptides for HLA–A⁄02:01, we focused on three
HLA–A⁄02:01 binding peptides, QVYPGLLEKV, TLYEAVRKV and
ILYAHLHKL. The three peptides were derived, by substitution of
non-anchor positions, from peptides present in the SYFPEITHI
database, and thus the chosen peptides would probably be
peptides conferring high-stability and/or non-facilitated (below a
deﬁned threshold of 1.5) by Tpn1–87. To also study a more tapasin-
dependent HLA-I molecule we selected HLA–B⁄08:01 and three
high-afﬁnity SYFPEITHI peptides for this allomorph. Predictions
based on an artiﬁcial neural network based tool (NetMHC 3.2)
[26,27] suggested that the synthesized peptides bind well to the
HLA–B⁄08:01 and HLA-A⁄02:01 respectively, and that the substitu-
tions in the peptides not signiﬁcantly alter their predicted afﬁnities
for HLA–A⁄02:01 (Table 1). We next experimentally determined
the afﬁnities, of the peptides to HLA–A⁄02:01 using an AlphaScreen
assay – an HLA-I binding assay in which dose-titrated amounts of
peptide is added to biotinylated HLA-I HC, b2m and presence or ab-
sence of Tpn1–87 allowing folding of pHLA-I complexes [23]. Under
conditions of limited receptor concentration ([HLA] 6 KD), the con-
centration of ligand leading to half-saturation (the EC50) is a rea-
sonable approximation of the equilibrium dissociation constant,
KD. After folding, streptavidin-coated AlphaScreen donor beads,
capturing the folded pHLA-I complexes, and acceptor beads conju-
gated with the MHC-I conformation speciﬁc antibody W6/32 are
added. Successfully folded pHLA-I complexes bound to donor
beads also bind W6/32 coated acceptor beads, creating a proximity
that allows diffusion of reactive oxygen species from the donor to
the acceptor bead, generating a luminescent signal to be released
and read in a plate reader. From the binding curves, EC50 values
were calculated conﬁrming that all the peptides were high afﬁnity
binders in the very upper end of the spectrum for binders to HLA–
A⁄02:01 (Table 2 and Fig. 1A). When Tpn1–87 was present during
the folding we observed a small increase in Bmax (i.e. 20–25%) for
folded pHLA–A⁄02:01 complexes (Fig. 1A–C), which should be
compared to the increase of Bmax of non-SYFPEITHI peptides that
typically are facilitated over 50–100% (see Supplementary Fig. 1)
[18]. We have previously deﬁned the ratio between the maximum
amount of folded complexes, Bmax, in the presence and absence of
Tpn1–87 as the Tpn1–87 facilitated folding [18]. Here, the tapasin facil-
itation was low (1.2–1.25) for all three pHLA–A⁄02:01 complexes,
consistent with the previous observations that binding of SYFPEI-
THI peptides to HLA–A⁄02:01 is only slightly or not at all facilitated
by Tpn1–87 [18]. As a control the mutant HLA–A⁄02:01-T134K mol-
ecule, that is not able to interact with tapasin [28], was used and
shown not to be facilitated regardless of what kind of peptide that
was supplied (Fig. 1B) [18,20]. Indeed, the tapasin-facilitation of
peptide binding was similar for both the wild type HLA–A⁄02:01
and the mutant HLA–A⁄02:01-T134K, further emphasizing the lack
of tapasin-facilitation for the here studied A⁄02:01 binding
peptides.Table 1
In silico predicted afﬁnities of HLA–A⁄02:01 and HLA–B⁄08:01 binding peptides.
Original
SYFPEITHI
Peptide
Predicted binding
afﬁnity (nM)
Modiﬁed
peptide
Predicted binding
afﬁnity (nM)
ILQAHLHSL 16 ILYAHLHKL 12
QVFPGLLERV 317 QVYPGLLEKV 394
TLYEAVREV 14 TLYEAVRKV 28
FLRGRAYGL 24
QAKWRLQTL 35
ELRSRYWAI 13The afﬁnities of the peptides binding to the more tapasin-
dependent allomorph HLA–B⁄08:01 conﬁrmed that also for this
allomorph the selected peptides were very good binders, although
with slightly lower afﬁnities than the HLA-A⁄02:01 peptides (i.e. a
low afﬁnity = a high EC50 value) (Table 2). The tapasin dependent
phenotype of HLA–B⁄08:01 was conﬁrmed based on a stronger
facilitation effect exerted by Tpn1–87. Indeed, two of the three SYF-
PEITHI peptides were facilitated above 1.5 (the threshold deter-
mined, from large sets of peptides, to discriminate SYFPEITHI
from non-SYFPEITHI binding to HLA–A⁄02:01), suggesting that dif-
ferent thresholds might be applicable for identiﬁcation of natural
ligands for different HLA-I allomorphs (Fig 1D).
3.2. pHLA–A⁄02:01 and pHLA–B⁄08:01 complexes differ in stability
depending on the bound peptide
Both HLA-I HC and peptide are important determinants of
tapasin-facilitation, but the exact factors that deﬁne pHLA-I tapa-
sin-facilitation are not known. Here, we set out to investigate the
relationship between tapasin-facilitation and stability of pHLA–
A⁄02:01 and pHLA–B⁄08:01. We measured the stability of the
pHLA–A⁄02:01 and pHLA–B⁄08:01 complexes using a biochemical
scintillation proximity assay [24]. In brief, 125I-labeled b2m and
HC was folded in the presence of peptide. After reaching steady
state, excess of unlabeled b2m was added to block re-association
of dissociated 125I-labeled b2 and the samples incubated at
+37 C, and the dissociation was followed continuously. Two of
the HLA–A⁄02:01 binding peptides, QVYPGLLEKV and TLYEAVRKV,
resulted in pHLA–A⁄02:01 complexes with similar stability (6.5
and 7.5 h respectively), while the ILYAHLHKL peptide produced
complexes with a half-life of 13.3 h (Fig. 2A). The difference be-
tween 6.5 and 7.5 h for QVYPGLLEKV and TLYEAVRKV respectively
and 13.3 h for ILYAHLHKL suggested a signiﬁcantly more stable
pHLA–A⁄02:01 complex for ILYAHLHKL. Moreover, to determine
whether Tpn1–87 would stabilize or de-stabilize the pHLA–
A⁄02:01 complexes at physiological temperature we also measured
the half-lives in the presence of Tpn1–87 (Fig. 2B). Consistent with a
previous study of other pHLA–A⁄02:01 complexes using the same
conditions we found that Tpn1–87 does not affect the dissociation
of pHLA–A⁄02:01 complexes [18].
Binding of each of the HLA–B⁄08:01 SYFPEITHI peptides re-
sulted in HLA–B⁄08:01 complexes of less stability than the
pHLA–A⁄02:01 complexes (Fig. 3A). The stability varied for the
pHLA–B⁄08:01 complexes but not in accordance to tapasin-facilita-
tion (Figs. 3D and 1D). A small but reproducible decrease in stabil-
ization in the presence of Tpn1–87 was seen for all the here studied
pHLA–B⁄08:01 complexes. All the pHLA-I dissociation data was ﬁt-
ted to biphasic dissociation curves (P-value < 0.0001) indicating
the presence of more than one pHLA-I species at time point 0. This
is in agreement with models of both MHC-I and HLA-II maturation
that include transition state of HLA complexes on their way to ﬁnal
maturation by optimization/exchange of their suboptimal peptide
[29–31].
A B C
D
Fig. 1. Tpn1–87 slightly facilitates folding of peptide–HLA–A⁄02:01 complexes and to a greater extent folding of peptide–HLA–B⁄08:01 complexes. Measurement of peptide-
binding afﬁnities (i.e. EC50), maximal folding and effect of Tpn1–87. (A) Recombinant HLA-A⁄02:01 heavy chain, or (B) recombinant HLA–A⁄02:01-T134K heavy chain, or (D)
recombinant HLA–B⁄08:01 heavy chain, and b2m was mixed with different concentrations of the indicated peptides. The molecules were allowed to fold into peptide–HLA-I
complexes in the absence (Ctrl) or presence (Tpn1–87) of excess Tpn1–87. The concentrations of folded peptide–HLA-complexes were measured using a biochemical
luminescence oxygen channeling immunoassay (LOCI), in which the MHC-I b2m-heavy chain conformation speciﬁc monoclonal antibody, W6/32, allows detection of folded
pHLA–A complexes. The maximum concentration of folded peptide–HLA-I complexes obtainable, Bmax, was calculated from the plateau at high peptide concentrations. The
peptide concentration required to reach half the value of Bmax is termed EC50, and is used as an approximation of the peptide binding afﬁnity to HLA-I. (C) A statistical
comparison of tapasin-facilitation of wild type HLA–A⁄02:01 and the mutant HLA–A⁄02:01-T134K. All experiments were done in duplicates, and standard deviations are
shown in each point. Experiment shown is representative out of three similar experiments.
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HLA-I matures inside the ER, and several ER proteins control the
maturation process. The ultimate purpose is to optimize the pHLA-I
complexes to generate efﬁcient pHLA-I display at the cell surface. In-
side the PLC, the HLA-I is kept in a peptide-receptive conformation
possibly enabling exchange of an already bound suboptimal peptide
with an optimal one, or alternatively trimming of a suboptimal pep-
tide already bound resulting in a more optimal version. Tapasin is
one of the ER proteins known to have a crucial role in HLA-I matura-
tion. Tapasin-deﬁcient cells have reduced HLA-I cell surface expres-
sion and the resulting pHLA-I complexes are less stable compared to
complexes fromwild type cells [2,4]. Interestingly, it has been foundthat different HLA-I molecules depend differently on tapasin for
efﬁcient cell surface expression, so that HLA–B⁄27:05 is hardly af-
fected by the absence of tapasin, whereas HLA–B⁄44:02 cannot be
expressed efﬁciently without tapasin [21]. HLA–A⁄02:01 is an inter-
mediary in terms of tapasin-dependency and is in addition one of
the most widely distributed HLA-I allomorphs. The degree of tapa-
sin-facilitation correlates with the tapasin-dependency determined
in cellular models with and without full length tapasin; and since it
has been shown that both stability and tapasin-facilitation are good
parameters to discriminate immunogenic from non-immunogenic
(i.e. SYFPEITHI fromnon-SYFPEITHI) HLA–A⁄02:01 binding peptides
a possible hypothesis is that the more stable the pHLA-I complex,
the less Tpn1–87 facilitation and vice versa [18].
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Fig. 2. Different stabilities, but no effect of Tpn1–87 on the stability of three different peptide–HLA–A⁄02:01 complexes. Peptide–HLA–A⁄02:01 complexes were folded with
125I-labeled b2m. An excess of unlabeled b2m was added and the dissociation of the complexes was initiated by incubating at +37 C. Bound radiolabeled b2m was read at the
time points indicated. (A) Dissociation of ILY, QVY and TLY–HLA–A⁄02:01 complexes. (B) Dissociation of ILY, QVY and TLY–HLA–A⁄02:01 complexes were monitored in the
presence or absence of Tpn1–87. All experiments were done in duplicates, data were ﬁtted in GraphPad (Prism) and best ﬁt was selected with P-value < 0.0001. The half-lives
were calculated as the time required to half the amount of bound labeled b2m. Experiment shown is representative out of three independent experiments. (C) The degree of
tapasin-facilitation plotted against the half-life of the peptide–HLA–A⁄02:01 complexes. The dotted line at tapasin-facilitation of 1.5 indicates the threshold for low/abscent
tapasin-facilitation for A⁄02:01, deﬁning the upper limit indicating immunogenic peptides.
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HLA–B⁄08:01 that have been registered in the SYFPEITHI database.
The peptides were predicted to be high-afﬁnity binders, and we
here conﬁrmed these predictions in a biochemical peptide–HLA-I
binding assay, and found that QVYPGLLEKV, TLYEAVRKV, ILY-
AHLHKL peptides were high afﬁnity binders to HLA–A⁄02:01 and
FLRGRAYGL, QAKWRLQTL, ELRSRYWAI to HLA-B⁄08:01 (Fig. 1 and
Table 2). We also found that all three HLA-A⁄02:01 peptides con-
ferred stable pHLA–A⁄02:01 complexes, although the pHLA–
A⁄02:01 complex with the ILYAHLHKL peptide was signiﬁcantly
more stable than the other pHLA–A⁄02:01 complexes despite equal
binding afﬁnity as TLYEAVRKV and QVYPGLLEKV to HLA–A⁄02:01
(Figs. 1 and 2). The folding of all pHLA–A⁄02:01 complexes were
equally unaffected by Tpn1–87 (i.e. tapasin-facilitation to very low
degrees (1.2–1.25)) (Fig 2C). These results are consistent with
observations of other pHLA–A⁄02:01 complexes [18], showing that
the folding of pHLA–A⁄02:01 complexes with half-lives above 2 h
are not readily facilitated by Tpn1–87.We also suggest that the sta-
bility for tapasin facilitated pHLA–A⁄02:01-complexes is in general
rather low (i.e. less than 2 h) [18], but there are also exceptions in
the direction of even less stable pHLA–A⁄02:01 complexes that still
not are Tpn1–87 facilitated (unpublished data, Geironson et al.),
hence the two criteria (i.e. low tapasin-facilitation and high stabil-
ity) are to a great extent deﬁning the same peptide pool but cau-
tion should be taken since there might be exceptions identiﬁed
only by one or the other of the selection tools (Fig. 4). In conclusion
for HLA–A⁄02:01, we here show, by using different peptides of highafﬁnity, that the stability of potential immunogenic pHLA–⁄02:01
complexes varies to a signiﬁcant extent but above a threshold
2 h, and that neither binding nor dissociation is affected by Tpn1–
87 for the here three studied high-afﬁnity peptides.
Also the stability for the pHLA–B⁄08:01 complexes varied sig-
niﬁcantly (i.e. 1.7–4.8 h). The pHLA–B⁄08:01 with the lowest
tapasin-facilitation was the intermediary pHLA-I complex in
terms of stability. It is worth again noting that tapasin-facilitation
differs for different HLA-I allomorphs and that a threshold (i.e.
1.5) has so far been deﬁned for HLA–A⁄02:01 only, separating
potentially immunogenic versus non-immunogenic peptides for
this allomorph [18]. For binding of peptides to HLA–A⁄02:01-
T134K no tapasin-facilitation is seen, neither with immunogenic
nor with non-immunogenic peptides, and for HLA–B⁄08:01 a
trend for separation based on tapasin-facilitation has been shown
although the threshold should most likely be set higher for this
allomorph. All the pHLA–B⁄08:01 had a lower stability than the
pHLA–A⁄02:01, which is in line with other data suggesting HLA-
B allomorphs to be less stable than HLA-A allmorphs (Harndahl
et al., manuscript in preparation). Moreover, a reproducible trend
suggesting a negative inﬂuence by Tpn1–87 on pHLA–B⁄08:01 sta-
bility in a dissociation assay at 37 C was seen. A destabilizing ef-
fect of Tpn1–87 was not seen for pHLA–A⁄02:01, which could
reﬂect the less tapasin-dependent nature of this allmorph. For
the highly tapasin-dependent allomorph HLA–B⁄44:02 an even
stronger destabilizing effect is seen (unpublished data, Geironson
et al.).
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Fig. 3. Different stabilities and a destabilizing tendency of Tpn1–87 on three different peptide–HLA–B⁄08:01 complexes. Peptide–HLA–B⁄08:01 complexes were folded with
125I labeled b2m. Excess unlabeled b2m was added and the dissociation of the complexes was initiated by incubating at +37 C. Bound radiolabeled b2m was read at the time
points indicated. (A) Dissociation of ILY, QVY and TLY-HLA–A⁄02:01 complexes. (B) After folding of FLR, QAK and ELR-HLA–A⁄08:01 complexes dissociation was monitored in
the presence or absence of Tpn1–87. All experiments were done in duplicates, data were ﬁtted to dissociation models and best ﬁt was selected with P-value < 0.0001, and the
half-lives were calculated as the time required to half the amount of bound labeled b2m. Experiment shown is representative out of two independent experiments. (C)
Dissociation curves of peptide–HLA–B⁄08:01 complexes in the presence and absence of Tpn1–87. (D) Degree of tapasin-facilitation plotted against the half-life of the peptide–
HLA-A⁄02:01 complexes. The dotted line at tapasin-facilitation of 1.5 indicates the threshold for low/abscent tapasin-facilitation for A⁄02:01.
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equilibria. The proportions of HLA-I in different phases have been
suggested to be dictated by HLA-I allomorph tapasin-dependence
(Fig. 5) [32]. The nature of dissociation of pMHC-I complexes is
inﬂuenced by several factors including peptide cargo, the presence
of tapasin, temperature and HLA-I allomorph [29]. A soluble tapa-
sin fos-jun zippered to HLA–B⁄08:01 has been shown, in a peptide
speciﬁc manner at 20 C, to shift biphasic dissociation with a high
half-life to monophasic dissociation with lower half-life. Our re-
sults are achieved from a stability assay at 37 C and show only a
trend for Tpn1–87 inﬂuence on dissociation, which is likely due both
to the temperature difference and the absence of binding forces
strong enough to allow the truncated Tpn1–87 to bind pHLA-I com-
plexes at these conditions. The here used stability assay conditions
are not ideal for the study of the very weak interactions between
Tpn1–87 and HLA-I molecules, or the effect of this, but are instead
good to provide information of HLA-I half-lives at physiological
temperature.
To design peptide-based vaccines it is crucial to be able to select
peptides with high immunogenic potential. In a study usingvaccinia virus (VACV) and HLA–A⁄02:01 as a model system it was
shown that only 15 epitopes out of >115,000 possible VACV-de-
rived 9- and 10-mer peptides were recognized after VACV infection
in HLA–A⁄02:01 transgenic mice [22]. There are several known as
well as unknown factors that contribute to this immunodominance
among peptides. The expression of viral proteins, the processing
and presentation, and the TCR repertoire as well as immune-regu-
latory mechanisms are all factors to have in mind when designing
peptide-based vaccines. To date the cleavage preferences for the
proteasome are known [33], as well as the preferences for human
TAP to transport into the ER in terms of peptide size, 8–12 amino
acids, and requirement of basic or hydrophobic amino acids at
the C-terminal [34]. The favoured amino acids for trimming of pep-
tides by ERAP1 and ERAP2 in the ER are also known [35]. Numer-
ous studies have resulted in the knowledge of the binding
preferences of peptides binding into the peptide-binding groove
of different HLA-I allomorphs. With all these parameters in mind
it is today possible to design peptides that with reasonable proba-
bility are immunogenic [36]. We recommend that to heighten this
probability the effect of tapasin function on HLA-I maturation
Fig. 4. Schematic model of tapasin-facilitation and pHLA-I stability as criteria for deﬁning immunogenic HLA-I binding peptides. (I) Simplistic perspective, (II), stability gives
a more accurate perspective, (III) realistic perspective, (IV) tapasin-facilitation gives a more accurate perspective.
Fig. 5. Scheme of peptide (p)–HLA-I complex formation and dissociation. HLA-I molecules mature through several stages and several equilibria. For HLA-I allomorphs of less
tapasin-dependent nature only a low proportion exist in disordered state and peptide binds into the peptide-binding groove, the reactions proceed with high speed to form a
mature locked pHLA-I (HLA-Ilocked). For less tapasin-dependent allomorphs the action of tapasin is less pronounced. HLA-I molecules of more tapasin-dependent nature have
been suggested to have a higher propensity for a disordered early state and for these molecules we suggest that tapasin plays an important role in driving the formation to
HLA-I forms of intermediary maturation grade, i.e. active HLA-I (HLA-Iactive), and pHLA-I in transition state (HLA-Itransition). These molecules have a peptide-receptive
conformation and peptide cargo allowing peptide to be exchanged or optimized. After folding, where steady state is reached, dissociation of less tapasin-dependent pHLA-I
complexes starts at time point zero with a majority of complexes in pHLA-Ilocked. Dissociation in the absence of tapasin may follow a bi-phase pattern while dissociation in the
presence of tapasin in a peptide-speciﬁc manner may drive all or a part of the pHLAlocked population to pHLAtransition with resulting mono or biphasic dissociation.
1342 L. Geironson et al. / FEBS Letters 586 (2012) 1336–1343should be taken into consideration. To date it is not known exactly
how tapasin exerts this HLA-I quality control. HLA-I molecules
binding to peptides with the same binding afﬁnities have been
shown to be facilitated by tapasin differently [18]. We have earlier
shown that stability and tapasin-facilitation are inversely corre-
lated and are both good tools to select immunogenic peptides
[18]. Moreover, in this study, we show data suggesting that both
tapasin-facilitation and stability of pHLA-I complexes deﬁneimmunogenic pHLA-I complexes but that the borders deﬁning
what stability is and what tapasin-facilitation is differs for different
HLA-I allomorphs.
In conclusion, we have here presented data showing that both
stability and tapasin-facilitation are HLA-I and peptide allomorph
speciﬁc features. Since all the peptides used in this study are likely
to be immunogenic, and with respect to the unique traits of each
HLA-I allomorph, we therefore propose that the low degree of
L. Geironson et al. / FEBS Letters 586 (2012) 1336–1343 1343tapasin-facilitation shown for the pHLA-I complexes studied here
further strengthens the concept of Tpn1–87 as a highly relevant tool,
that together with stability can be used to deﬁne immunogenic
peptides.
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